Table 5.
Association of WHO Stage 3 and 4 conditions during the first six months of antiretroviral treatment with mortality at 36 months
| WHO condition (during first six months ARV) | Mortality all patients uHR (95% CI), p-value | Mortality age 15 to 50 uHR (95% CI), p-value | Mortality age >50 uHR (95% CI), p-value | Mortality age >50 (vs 15 to 50) uHR (95% CI), p-value |
|---|---|---|---|---|
| WHO Stage 3 condition | ||||
| Weight loss >10% | 2.51 (1.72, 3.64), <0.001 | 2.61 (1.75, 3.87), <0.001 | 1.49 (0.47, 4.67), 0.497 | 1.07 (0.32, 3.56), 0.908 |
| Diarrhoea, unexplained | 1.80 (1.15, 2.83), 0.011 | 1.93 (1.20, 3.12), 0.007 | 0.84 (0.21, 3.40), 0.808 | 0.83 (0.19, 3.59), 0.801 |
| Fever, unexplained | 2.31 (1.47, 3.64), <0.001 | 2.53 (1.59, 4.03), <0.001 | 0.75 (0.10, 5.35), 0.773 | 0.55 (0.07, 4.11), 0.558 |
| Oral candidiasis | 1.61 (1.28, 2.02), <0.001 | 1.57 (1.22, 2.00), <0.001 | 1.47 (0.83, 2.60), 0.186 | 1.75 (0.97, 3.17), 0.064 |
| Pulmonary TB | 1.97 (1.60, 2.42), <0.001 | 2.06 (1.66, 2.56), <0.001 | 1.15 (0.54, 2.45), 0.727 | 1.02 (0.47, 2.21), 0.956 |
| Bacterial pneumonia | 2.01 (1.32, 3.06), 0.001 | 2.10 (1.35, 3.26), 0.001 | 1.19 (0.29, 4.79), 0.811 | 1.08 (0.25, 4.63), 0.914 |
| Bacterial infections, severe, including pneumonia | 1.92 (1.06, 3.48), 0.031 | 2.03 (1.09, 3.78), 0.026 | 0.99 (0.14, 7.11), 0.996 | 1.10 (0.14, 8.61), 0.930 |
| Oral hairy leukoplakia | 0.99 (0.73, 1.34), 0.951 | 0.91 (0.65, 1.27), 0.579 | 1.98 (0.93, 4.24), 0.077 | 3.94 (1.75, 8.85), 0.001 |
| Lymph node TB | 0.53 (0.07, 3.75), 0.523 | 0.57 (0.08, 4.07), 0.577 | ** | ** |
| WHO Stage 4 condition | ||||
| Wasting syndrome by HIV/stunting/severe malnutrition | 3.73 (2.49, 5.59), <0.001 | 4.15 (2.72, 6.32), <0.001 | 1.27 (0.31, 5.11), 0.741 | 0.64 (0.15, 2.73), 0.548 |
| Cryptococcosis extrapulmonary | 3.04 (2.02, 4.60), <0.001 | 3.38 (2.23, 5.10), <0.001 | ** | ** |
| Pneumocystis pneumonia | 1.95 (1.13, 3.37), 0.016 | 2.16 (1.25, 3.73), 0.006 | ** | ** |
| Toxoplasmosis of the brain | 2.95 (1.99, 4.39), <0.001 | 3.03 (2.03, 4.54), <0.001 | 3.67 (0.51, 26.23), 0.195 | 2.02 (0.27, 14.94), 0.492 |
| Penicillium marneffei infection | 2.73 (1.47, 5.09), 0.002 | 3.03 (1.63, 5.65), <0.001 | ** | ** |
| Candidiasis oesophagus/trachea/bronchi/lungs | 2.96 (2.07, 4.23), <0.001 | 2.89 (1.97, 4.23), <0.001 | 3.41 (1.26, 9.22), 0.016 | 2.15 (0.75, 6.15), 0.153 |
| Extrapulmonary TB | 2.43 (1.87, 3.16), <0.001 | 2.60 (1.99, 3.40), <0.001 | 0.91 (0.22, 3.66), 0.891 | 0.71 (0.17, 2.90), 0.631 |
| Lymphoma | 5.81 (1.45, 23.27), 0.013 | 6.11 (1.53, 24.45), 0.011 | ** | ** |
| Herpes simplex infection | 1.10 (0.52, 2.31), 0.807 | 1.06 (0.47, 2.36), 0.889 | 1.30 (0.18, 9.27), 0.796 | 2.41 (0.29, 20.05), 0.417 |
| Non-TB mycobacteria infection | 2.68 (2.02, 3.56), <0.001 | 2.87 (2.15, 3.84), <0.001 | 1.04 (0.26, 4.22), 0.953 | 0.66 (0.16, 2.73), 0.571 |
| Mycosis disseminated | 1.62 (0.87, 3.02), 0.128 | 1.48 (0.74, 2.97), 0.266 | 2.17 (0.54, 8.77), 0.276 | 2.75 (0.58, 12.97), 0.201 |
| Kaposi's sarcoma | 6.34 (4.54, 8.87), <0.001 | 5.84 (4.01, 8.49), <0.001 | 8.04 (3.75, 17.24), <0.001 | 2.40 (1.05, 5.51), 0.038 |
| Cytomegalovirus infection | 2.49 (1.47, 4.21), 0.001 | 2.78 (1.64, 4.71), <0.001 | ** | ** |
**
No diagnosis of this WHO condition made in this age group. uHR, unadjusted hazard ratio; CI, confidence interval; TB, tuberculosis.